Highlights
NASDAQ: EXEL       Exelixis Inc
Last Price Today's Change   Day's Range   Trading Volume
17.545   -0.195 (1.10%)  17.445 - 18.10  453,840

Overview

 
Avg Volume (4 weeks):3,724,905
4 Weeks Range:16.69 - 20.76
4 Weeks Price Volatility (%):
21.01%
52 Weeks Range:15.02 - 25.31
52 Weeks Price Volatility (%):
24.54%
Average Price Target: 9.00
Price Target Upside/Downside: -8.545

Headlines



No recent Headlines for this stock.


Business Background

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

  Be the first to like this.
 


 

3335  2069  500  3058 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 CELG 108.24+0.11 
 ACHN 6.760.00 
 AVP 5.60-0.05 
 AABA 19.630.00 
 VIAB 24.22+0.75 
 ECA 3.79-0.25 
 VXRT 0.90+0.258 
 PFE 38.53-1.63 
 NIO 4.155+0.145 
 BBT 54.24+0.75 
Partners & Brokers